Generic Drug Review June 2016
An Overview of Generic Angiotensin Receptor Blockers
ARBs are first-line agents for patients with hypertension and comorbid chronic kidney disease.
Generic Drug Industry Update From the GPhA
The GPhA and many health stakeholders are waiting for the finalization of the FDA’s Proposed Rule to update generic drug labeling requirements.
Insights Into Effective Generic Substitution
As drug costs surge, generic drug substitution will continue to play a crucial role in reducing healthcare costs and improving access to healthcare.
New Generics in the Pipeline
These nonbranded medications, expected to be available in the United States over the next 5 years, will have therapeutic as well as financial impact.
Patent & Regulatory Exclusivities: The Two Keys Driving Generic and Follow-on Market Availability
In order to help balance innovation in the pharmaceutical industry with affordable and equitable access to medications, the FDA has typically relied on two key systems: intellectual property (patent) exclusivity and regulatory (market) exclusivity.
Patient Perceptions of Generic Drugs: Dispelling Misconceptions
As national healthcare spending continues to rise, the use of generic medications is encouraged by insurers and the federal government as a cost-saving strategy.
Continuing Education
$7.95 Per CE Exam or $69 for 12 Lessons
-
• April 2026 • 2.00 Credits
Managing HIV Coinfections and Complications
-
Pain Management • March 2026 • 2.00 Credits
Updated Guidance for Opioid Use in Pain Management
-
Cardiovascular • February 2026 • 2.00 Credits
Managing Modifiable Risk Factors in Chronic Coronary Disease
Copyright © 2000 - 2024 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.